Home > Research > Publications & Outputs > Glucagon-like peptide-1 analogues enhance synap...
View graph of relations

Glucagon-like peptide-1 analogues enhance synaptic plasticity in the brain: a link between diabetes and Alzheimer's disease

Research output: Contribution to Journal/MagazineJournal articlepeer-review

<mark>Journal publication date</mark>25/03/2010
<mark>Journal</mark>European Journal of Pharmacology
Issue number1-3
Number of pages5
Pages (from-to)158-162
Publication StatusPublished
<mark>Original language</mark>English


Type 2 diabetes has been identified as a risk factor for patients with Alzheimer's disease. Insulin signalling is often impaired in Alzheimer's disease, contributing to the neurodegenerative process. One potential strategy to help prevent this is the normalisation of insulin signalling in the brain. Therefore, the present study was designed to test the effects of novel enzyme-resistant analogues of the insulin-releasing incretin hormone, glucagon-like peptide 1 (GLP-1). The effects of Liraglutide (Victoza) and other novel GLP-1 analogues were tested on synaptic plasticity (LTP) in area CA1 of the hippocampus. At a dose of 15nmol in 5microl i.c.v., Liraglutide (P